For patient 32, the post-resistance tumor sample had a clonal ERBB2L869R activating mutation that was also present in the pre-treatment sample, as well as an acquired ERBB2 focal high amplification (copy number above ploidy from 1.9 to 9.7) not found in the pre-treatment sample. Here, ERBB2 is linked to neoplasm.